Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that treatment with spironolactone significantly improved pain, inflammatory lesion count, and HS-PGA scores among female patients with hidradenitis suppurativa, suggesting its potential as an effective treatment option, even at lower doses, despite no change in Hurley stage or fistula count.

Intense pulsed light with radiofrequency showed mixed results in improving quality of life for hidradenitis suppurativa patients, with no clinical improvements.

This study found that spironolactone significantly reduced pain, lesion count, and disease severity in patients with hidradenitis suppurativa, as reported in multiple patient cohorts.

This study found that patients with hidradenitis suppurativa had lower trabecular bone score and total hip bone mineral density compared to controls, with a high prevalence of vitamin D deficiency.

This study found that the clinical severity of hidradenitis suppurativa, evaluated through Hurley staging, VAS, PGA, and SAHS, significantly affects patients' work absenteeism and presenteeism, with presenteeism being more prevalent.

In this study, microneedle-assisted delivery of polyglutamate significantly improved hair parameters, scalp symptoms, and quality of life in androgenetic alopecia patients, with no serious adverse reactions reported.

This study found that PGA-4HGF nanoparticles enhanced hair growth in mice more effectively than 4HGF alone by increasing anagen phase duration and dermal papilla cell proliferation.

In this study, the researchers reported that patient impacts and symptoms of hidradenitis suppurativa, as assessed by HSIA and HSSA measures, are associated with clinical characteristics such as the number of abscesses and inflammatory nodules.

This review develops expert-guided recommendations for hidradenitis suppurativa management, highlighting evidence for the effectiveness of antibacterial and anti-tumor necrosis factor therapies, but reports no new clinical trial results.

This article reviews the prevalence, causes, and associated conditions of hidradenitis suppurativa, a chronic inflammatory skin disease, but reports no new clinical findings.

This study suggests that the hydrogel nanoparticle formulation of hair growth-promoting compounds may enhance hair follicle penetration and induce hair growth in tested models, demonstrating its potential as a hair growth treatment.

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This review explores the hormonal factors related to hidradenitis suppurativa, emphasizing insulin resistance and pro-inflammatory adipokines, but reports no new clinical findings and suggests further research is needed.

This article reviews various medical treatments for hidradenitis suppurativa based on the author's experience with over 350 patients, but it reports no new clinical findings.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This review highlights that while pharmacotherapy, including biological agents, provides varying but often partial control of hidradenitis suppurativa depending on disease severity, significant challenges and high relapse rates persist, necessitating further research for more effective treatments.

In this cross-sectional study, researchers observed that patients with hidradenitis suppurativa, particularly women, had lower 2D:4D finger length ratios compared to healthy controls, suggesting a potential link to prenatal androgen exposure and disease severity, though further prospective research is needed to confirm this hormonal impact.

This study suggests that finasteride is a safe and effective alternative therapy for women with hidradenitis suppurativa who have contraindications or intolerance to spironolactone.

This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.

The researchers reported that the facial Psoriasis Log-based Area and Severity Index (fPLASI) more reliably and sensitively captured clinical improvement in facial psoriasis than the existing facial Psoriasis Area and Severity Index (fPASI).

In this study, the Peninsula Timerevert Needle was found to provide effective treatment for skin photoaging and acne scars with less pain and shorter treatment duration compared to EndyMed, although it caused more bleeding.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This study observed that gold thread implantation increased hair regrowth in both human patients and mice, suggesting it could be an effective hair regrowth treatment, although further studies are needed to understand its mechanisms and safety.

This case report describes regression of hidradenitis suppurativa lesions in two patients after 16 weeks of adalimumab treatment.

This study found that adalimumab treatment led to regression of lesions in two patients with hidradenitis suppurativa after 16 weeks of therapy.

This review compares European and U.S. treatment guidelines for hidradenitis suppurativa and reports no definitive standard, highlighting the need for more randomized controlled trials.

This review provides graded evidence and a therapeutic algorithm for managing hidradenitis suppurativa, but does not present new clinical results.

This symposium updated participants on the latest advances in understanding and managing hidradenitis suppurativa, emphasizing the need for individualized treatment plans and highlighting recent progress in therapies and epidemiology.